The Germany Insulin Infusion Pump Market size is estimated at USD 130.69 million in 2024, and is expected to reach USD 148.88 million by 2029, growing at a CAGR of 2.64% during the forecast period (2024-2029).
Diabetes patients are more likely than non-diabetics to have significant problems. Diabetic medicine makers took care during COVID-19 to ensure that pharmaceuticals were delivered to diabetic patients with the assistance of local governments. "Since the start of COVID-19, our commitment to patients, our employees, and the communities where we operate has remained unchanged," Novo Nordisk stated on its website. "We continue to supply our medicines and devices to people living with diabetes and other serious chronic diseases, safeguard the health of our employees, and take actions to support doctors and nurses as they work to defeat COVID-19."
Germany is one of the industrialized nations with cutting-edge medical facilities. Diabetes mellitus is classified into several categories. Hyperglycemia, or high blood sugar, is a typical new-onset symptom. The most common types of diabetes include type-1 diabetes, type-2 diabetes, and gestational diabetes. Other types occur on a less frequent basis. Type-2 diabetes will grow increasingly common in Germany during the next twenty years. According to DZD experts, up to 12 million people may develop a metabolic illness by 2040. The fast growth in type-1 and type-2 diabetes among the elderly poses considerable challenges for the German healthcare system.
Diabetes is associated with many health complications. Comparing the population with and without diabetes, those with diabetes have an increased risk of being hospitalized and, thus, incur more healthcare expenses compared to non-diabetic people. People with diabetes face a higher chance of experiencing serious complications. Germany is one of the developed countries and advanced in terms of healthcare facilities. Technologies, such as insulin infusion pumps and continuous glucose monitoring are getting more adopted rapidly in Germany than the other developing countries. Moreover, the reimbursement policy and the pricing policy are highly regulated, which drives the market and increases the adoption rate of new and advanced technologies.
Insulin pump therapy is very important for children and adolescents with type 1 diabetes, and clinical recommendations strongly recommend it. The regularity with which glucose levels are monitored is determined by the type of diabetes, which varies from patient to patient. Type-1 diabetes patients must check their blood glucose levels regularly, monitor them, and modify their insulin dose accordingly, expected to drive market growth throughout the projected period. Continuous subcutaneous insulin infusion and glucose monitoring devices have significantly improved patient care and quality of life and are now routinely utilized in ambulatory care. This technology is increasingly being employed in the healthcare setting.
In Germany, insulin pump treatment was used by more than half of children and adolescents with type-1 diabetes. Insulin pump use has steadily grown, with females outnumbering boys. Insulin pump treatment allows persons with type-1 diabetes more freedom and more physiological insulin delivery. According to research, insulin pump treatment can improve blood sugar management. Owing to the above factors, the market will likely continue to grow.
Diabetes, a significant health concern, is one of the astonishing difficulties confronting Germany's healthcare facilities. The prevalence of recognized type-1 and type-2 diabetes in the German adult population is rather high, with many people who have not yet been diagnosed. The incidence of type-2 diabetes is expected to climb gradually in the coming years due to an aging population and an unhealthy lifestyle. High-quality therapy, including adequate monitoring, risk factor reduction, and active self-management, is essential in reducing complications in German type-2 diabetes patients.
As a consequence of the factors above, the investigated market is predicted to grow during the investigation.
This product will be delivered within 2 business days.
Diabetes patients are more likely than non-diabetics to have significant problems. Diabetic medicine makers took care during COVID-19 to ensure that pharmaceuticals were delivered to diabetic patients with the assistance of local governments. "Since the start of COVID-19, our commitment to patients, our employees, and the communities where we operate has remained unchanged," Novo Nordisk stated on its website. "We continue to supply our medicines and devices to people living with diabetes and other serious chronic diseases, safeguard the health of our employees, and take actions to support doctors and nurses as they work to defeat COVID-19."
Germany is one of the industrialized nations with cutting-edge medical facilities. Diabetes mellitus is classified into several categories. Hyperglycemia, or high blood sugar, is a typical new-onset symptom. The most common types of diabetes include type-1 diabetes, type-2 diabetes, and gestational diabetes. Other types occur on a less frequent basis. Type-2 diabetes will grow increasingly common in Germany during the next twenty years. According to DZD experts, up to 12 million people may develop a metabolic illness by 2040. The fast growth in type-1 and type-2 diabetes among the elderly poses considerable challenges for the German healthcare system.
Diabetes is associated with many health complications. Comparing the population with and without diabetes, those with diabetes have an increased risk of being hospitalized and, thus, incur more healthcare expenses compared to non-diabetic people. People with diabetes face a higher chance of experiencing serious complications. Germany is one of the developed countries and advanced in terms of healthcare facilities. Technologies, such as insulin infusion pumps and continuous glucose monitoring are getting more adopted rapidly in Germany than the other developing countries. Moreover, the reimbursement policy and the pricing policy are highly regulated, which drives the market and increases the adoption rate of new and advanced technologies.
Germany Insulin Infusion Pump Market Trends
Insulin Pump is Expected to Witness Growth Over the Forecast Period
An insulin pump is a device that continuously or, as needed, distributes insulin. The pump is modeled after the human pancreas. The insulin infusion pump can be used instead of a daily injection regimen or an insulin pen. Insulin pump treatment is a popular technique of insulin delivery for people with type 1 diabetes (T1DM). Pumps are a well-known and tried-and-true therapeutic option for T1DM patients of all ages, providing near-physiological insulin administration when the pancreas fails to generate insulin. Remote-controlled insulin pumps allow parents to suspend or bolus insulin from a safe distance while their child is playing or eating.Insulin pump therapy is very important for children and adolescents with type 1 diabetes, and clinical recommendations strongly recommend it. The regularity with which glucose levels are monitored is determined by the type of diabetes, which varies from patient to patient. Type-1 diabetes patients must check their blood glucose levels regularly, monitor them, and modify their insulin dose accordingly, expected to drive market growth throughout the projected period. Continuous subcutaneous insulin infusion and glucose monitoring devices have significantly improved patient care and quality of life and are now routinely utilized in ambulatory care. This technology is increasingly being employed in the healthcare setting.
In Germany, insulin pump treatment was used by more than half of children and adolescents with type-1 diabetes. Insulin pump use has steadily grown, with females outnumbering boys. Insulin pump treatment allows persons with type-1 diabetes more freedom and more physiological insulin delivery. According to research, insulin pump treatment can improve blood sugar management. Owing to the above factors, the market will likely continue to grow.
Rising diabetes prevalence in the country is anticipated to boost the market studied
In recent years, Germany has seen an alarming increase in the prevalence of diabetes. Patients with diabetes must make several adjustments during the day to maintain minimal blood glucose levels. These adjustments include taking anti-diabetic medication or eating more carbs while monitoring their blood glucose levels. Obesity, a poor diet, and physical inactivity contribute to a rise in newly diagnosed Type-1 and Type-2 diabetes cases. The fast-growing incidence and prevalence of diabetes patients and healthcare spending are indicators of increased diabetic device use. Strict government controls and favorable WHO regulations controlling the use of insulin pumps in Germany stimulate companies to develop unique products. The availability of these companies on the German market facilitates the conduct of clinical trials by regional clinical research organizations (CROs). It provides management simplicity, which speeds up the discovery process. According to the German Diabetes Centre (DDZ), at least 7.2% of the German population now has diabetes, which is expected to rise dramatically over the next two decades. Under German law, public insurance must limit out-of-pocket healthcare expenditures and cover all medically required treatment, including insulin. According to T1 International, an advocacy organization for persons with type-1 diabetes, German diabetes patients enjoy among the lowest out-of-pocket insulin prices in the world.Diabetes, a significant health concern, is one of the astonishing difficulties confronting Germany's healthcare facilities. The prevalence of recognized type-1 and type-2 diabetes in the German adult population is rather high, with many people who have not yet been diagnosed. The incidence of type-2 diabetes is expected to climb gradually in the coming years due to an aging population and an unhealthy lifestyle. High-quality therapy, including adequate monitoring, risk factor reduction, and active self-management, is essential in reducing complications in German type-2 diabetes patients.
As a consequence of the factors above, the investigated market is predicted to grow during the investigation.
Germany Insulin Infusion Pump Industry Overview
Due to the existence of only a few big businesses operating internationally and locally, the insulin infusion pump industry is concentrated. The competitive landscape includes examining a few well-known worldwide and local organizations, such as Medtronic PLC, Insulet Corporation, Ypsomed, Ascensia Diabetes Care, and Tandem Diabetes Care.Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION
6 MARKET INDICATORS
7 COMPETITIVE LANDSCAPE
Methodology
LOADING...
